Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | carboxylesterase | 0.0246 | 0.3328 | 0.3328 |
Toxoplasma gondii | 3-oxo-5-alpha-steroid 4-dehydrogenase | 0.0655 | 1 | 1 |
Mycobacterium tuberculosis | POSSIBLE PARA-NITROBENZYL ESTERASE (FRAGMENT) | 0.0041 | 0 | 0.5 |
Echinococcus multilocularis | synaptic glycoprotein sc2 | 0.0129 | 0.1432 | 0.4304 |
Trichomonas vaginalis | synaptic glycoprotein sc2, putative | 0.0129 | 0.1432 | 0.1432 |
Loa Loa (eye worm) | hypothetical protein | 0.0246 | 0.3328 | 0.3328 |
Mycobacterium ulcerans | hypothetical protein | 0.0655 | 1 | 1 |
Brugia malayi | Carboxylesterase family protein | 0.0246 | 0.3328 | 0.3328 |
Trypanosoma cruzi | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | 0.0655 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0129 | 0.1432 | 0.1432 |
Trichomonas vaginalis | synaptic glycoprotein sc2, putative | 0.0129 | 0.1432 | 0.1432 |
Trichomonas vaginalis | synaptic glycoprotein sc2, putative | 0.0129 | 0.1432 | 0.1432 |
Schistosoma mansoni | family S9 non-peptidase homologue (S09 family) | 0.0246 | 0.3328 | 1 |
Echinococcus multilocularis | 3 oxo 5 alpha steroid 4 dehydrogenase, C terminal | 0.0129 | 0.1432 | 0.4304 |
Giardia lamblia | Synaptic glycoprotein SC2 | 0.0129 | 0.1432 | 0.5 |
Trichomonas vaginalis | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | 0.0655 | 1 | 1 |
Plasmodium falciparum | polyprenol reductase, putative | 0.0129 | 0.1432 | 0.5 |
Trichomonas vaginalis | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | 0.0655 | 1 | 1 |
Leishmania major | 3-oxo-5-alpha-steroid 4-dehydrogenase-like protein | 0.0655 | 1 | 0.5 |
Brugia malayi | Synaptic glycoprotein SC2 | 0.0129 | 0.1432 | 0.1432 |
Trichomonas vaginalis | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | 0.0655 | 1 | 1 |
Echinococcus granulosus | acetylcholinesterase | 0.0246 | 0.3328 | 1 |
Loa Loa (eye worm) | acetylcholinesterase 1 | 0.0246 | 0.3328 | 0.3328 |
Echinococcus multilocularis | acetylcholinesterase | 0.0246 | 0.3328 | 1 |
Plasmodium vivax | polyprenol reductase, putative | 0.0129 | 0.1432 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0129 | 0.1432 | 0.1432 |
Echinococcus multilocularis | acetylcholinesterase | 0.0246 | 0.3328 | 1 |
Mycobacterium tuberculosis | Carboxylesterase LipT | 0.0041 | 0 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0129 | 0.1432 | 0.1432 |
Loa Loa (eye worm) | hypothetical protein | 0.0246 | 0.3328 | 0.3328 |
Trypanosoma brucei | 3-oxo-5-alpha-steroid 4-dehydrogenase-like, putative | 0.0655 | 1 | 1 |
Entamoeba histolytica | steroid 5-alpha reductase, putative | 0.0655 | 1 | 1 |
Schistosoma mansoni | synaptic glycoprotein sc2 related | 0.0129 | 0.1432 | 0.4304 |
Trypanosoma cruzi | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | 0.0655 | 1 | 1 |
Schistosoma mansoni | synaptic glycoprotein sc2 related | 0.0129 | 0.1432 | 0.4304 |
Loa Loa (eye worm) | hypothetical protein | 0.0129 | 0.1432 | 0.1432 |
Brugia malayi | Carboxylesterase family protein | 0.0246 | 0.3328 | 0.3328 |
Echinococcus granulosus | acetylcholinesterase | 0.0246 | 0.3328 | 1 |
Trichomonas vaginalis | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | 0.0129 | 0.1432 | 0.1432 |
Echinococcus multilocularis | carboxylesterase 5A | 0.0246 | 0.3328 | 1 |
Plasmodium falciparum | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | 0.0129 | 0.1432 | 0.5 |
Plasmodium vivax | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | 0.0129 | 0.1432 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0655 | 1 | 1 |
Echinococcus granulosus | carboxylesterase 5A | 0.0246 | 0.3328 | 1 |
Echinococcus granulosus | synaptic glycoprotein sc2 | 0.0129 | 0.1432 | 0.4304 |
Echinococcus granulosus | 3 oxo 5 alpha steroid 4 dehydrogenase C terminal | 0.0129 | 0.1432 | 0.4304 |
Onchocerca volvulus | 0.0129 | 0.1432 | 1 | |
Mycobacterium tuberculosis | POSSIBLE PARA-NITROBENZYL ESTERASE (FRAGMENT) | 0.0041 | 0 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.